Eli Lilly won FDA approval on 1 April 2026 for a once-daily oral GLP-1, orforglipron. Read more about the drug and its ...

TENS significantly reduces movement related pain in fibromyalgia, with sustained benefits and strong patient reported ...

Hospital crisis decision-making may protect preparedness but sideline other services during emergencies. Read more.

Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.

Hospital-acquired pneumonia remains a major ICU threat as new diagnostics and tailored treatment strategies reshape care.

Read more about the settings in which applying antiseptics to the umbilical cord can reduce infection and mortality risk.

Lupus nephritis biomarkers show promise, but most lack strong evidence for clinical use. Read more on key findings.

Rapid testing identifies acute respiratory distress syndrome subtypes linked to mortality, supporting precision medicine in ...

Clare Morlidge and Katie Vinen. Consultant Renal Pharmacist, East and North Hertfordshire NHS Trust, UK; Co-President, UK ...

Deucravacitinib showed strong psoriasis control and rapid scalp clearance with mild adverse events in real-world practice.

Pharma companies are facing renewed pressure as instability linked to the Middle East conflict affects both supply chains and ...

The findings are notable because thrombotic complications are often emphasized in cancer care, yet this analysis found that ...